1	Bristol-Myers	NNP	2	nn
2	Squibb	NNP	3	nn
3	Co.	NNP	16	nsubj
4	,	,	3	punct
5	New	NNP	6	nn
6	York	NNP	3	appos
7	,	,	3	punct
8	the	DT	14	det
9	newly	RB	10	advmod
10	merged	VBN	14	amod
11	drug	NN	14	nn
12	and	CC	11	cc
13	health-care-product	NN	11	conj
14	company	NN	3	dep
15	,	,	3	punct
16	reported	VBD	0	root
17	record	NN	19	nn
18	third-quarter	NN	19	nn
19	earnings	NNS	16	dobj
20	for	IN	19	prep
21	both	DT	22	det
22	companies	NNS	20	pobj
23	in	IN	22	prep
24	the	DT	25	det
25	merger	NN	23	pobj
26	.	.	16	punct

1	Bristol-Myers	NNP	2	nn
2	Co.	NNP	11	nsubj
3	and	CC	2	cc
4	Squibb	NNP	5	nn
5	Corp.	NNP	2	conj
6	,	,	5	punct
7	Princeton	NNP	5	appos
8	,	,	7	punct
9	N.J.	NNP	7	appos
10	,	,	7	punct
11	merged	VBD	0	root
12	Oct.	NNP	11	tmod
13	4	CD	12	num
14	,	,	11	punct
15	but	CC	11	cc
16	the	DT	18	det
17	new	JJ	18	amod
18	company	NN	19	nsubj
19	reported	VBD	11	conj
20	third-period	JJ	21	amod
21	earnings	NNS	19	dobj
22	for	IN	21	prep
23	both	DT	24	det
24	companies	NNS	22	pobj
25	.	.	11	punct

1	For	IN	9	prep
2	the	DT	4	det
3	fourth	JJ	4	amod
4	quarter	NN	1	pobj
5	,	,	9	punct
6	Bristol-Myers	NNP	7	nn
7	Squibb	NNP	9	nsubj
8	will	MD	9	aux
9	report	VB	0	root
10	one	CD	11	num
11	set	NN	9	dobj
12	of	IN	11	prep
13	earnings	NNS	12	pobj
14	.	.	9	punct

1	Bristol-Myers	NNP	2	nsubj
2	said	VBD	0	root
3	net	JJ	4	amod
4	income	NN	5	nsubj
5	rose	VBD	2	ccomp
6	15	CD	7	num
7	%	NN	5	dobj
8	to	TO	5	prep
9	$	$	8	pobj
10	266.2	CD	9	number
11	million	CD	9	number
12	,	,	9	punct
13	or	CC	9	cc
14	93	CD	15	num
15	cents	NNS	9	conj
16	a	DT	17	det
17	share	NN	15	npadvmod
18	,	,	9	punct
19	from	IN	5	prep
20	$	$	19	pobj
21	232.3	CD	20	number
22	million	CD	20	number
23	,	,	20	punct
24	or	CC	20	cc
25	81	CD	26	num
26	cents	NNS	20	conj
27	a	DT	28	det
28	share	NN	26	npadvmod
29	,	,	20	punct
30	a	DT	31	det
31	year	NN	32	npadvmod
32	earlier	RBR	19	advmod
33	.	.	2	punct

1	Sales	NNS	2	nsubj
2	gained	VBD	0	root
3	5	CD	4	num
4	%	NN	2	dobj
5	to	TO	2	prep
6	$	$	5	pobj
7	1.59	CD	6	number
8	billion	CD	6	number
9	from	IN	2	prep
10	$	$	9	pobj
11	1.52	CD	10	number
12	billion	CD	10	number
13	.	.	2	punct

1	Squibb	NNP	2	nn
2	Corp.	NNP	3	nsubj
3	said	VBD	0	root
4	net	NN	5	nsubj
5	rose	VBD	3	ccomp
6	17	CD	7	num
7	%	NN	5	dobj
8	to	TO	5	prep
9	$	$	8	pobj
10	144.5	CD	9	number
11	million	CD	9	number
12	,	,	9	punct
13	or	CC	9	cc
14	$	$	9	conj
15	1.47	CD	14	num
16	a	DT	17	det
17	share	NN	14	npadvmod
18	,	,	9	punct
19	from	IN	5	prep
20	$	$	19	pobj
21	123	CD	20	number
22	million	CD	20	number
23	,	,	20	punct
24	or	CC	20	cc
25	$	$	20	conj
26	1.25	CD	25	num
27	a	DT	28	det
28	share	NN	25	npadvmod
29	.	.	3	punct

1	Sales	NNS	3	nsubj
2	were	VBD	3	cop
3	$	$	0	root
4	730.1	CD	3	number
5	million	CD	3	number
6	,	,	3	punct
7	up	IN	3	advmod
8	7	CD	9	num
9	%	NN	7	pobj
10	from	IN	7	prep
11	$	$	10	pobj
12	679.5	CD	11	number
13	million	CD	11	number
14	.	.	3	punct

1	In	IN	11	prep
2	New	NNP	3	nn
3	York	NNP	5	nn
4	Stock	NNP	5	nn
5	Exchange	NNP	7	nn
6	composite	JJ	7	amod
7	trading	NN	1	pobj
8	,	,	11	punct
9	Bristol-Myers	NNP	10	nn
10	Squibb	NNP	11	nsubj
11	rose	VBD	0	root
12	$	$	11	dobj
13	1.75	CD	12	num
14	to	TO	11	prep
15	$	$	14	pobj
16	52.75	CD	15	num
17	.	.	11	punct


